Monthly Cost Comparison: Wegovy vs Mounjaro Pricing
Understanding the Monthly Cost When Switching From Wegovy to Mounjaro
When evaluating a change from Wegovy to Mounjaro, the monthly cost difference represents a significant factor in treatment selection. Wegovy follows a structured 16-week dose escalation protocol, with monthly costs ranging from £79.99 for the 0.25mg starter dose to £209.99 for the 2.4mg maintenance dose, while Mounjaro operates on a different pricing structure with its own escalation schedule. The decision to change from Wegovy to Mounjaro monthly cost considerations extends beyond simple price comparison, as each medication requires different dose titration periods and maintenance schedules.
Both prescription-only medicines require ongoing monthly investment, but the timing and total annual costs differ substantially between treatments. Wegovy's maintenance phase begins at week 17 with consistent £209.99 monthly costs, whereas Mounjaro's pricing structure follows a different pattern that may influence your long-term budget planning. EverydayMeds provides transparent pricing for both options, ensuring patients can make informed financial decisions when considering this medication switch.
Detailed Wegovy Pricing Structure vs Mounjaro Costs
Wegovy pricing follows NHS-approved dose escalation: 0.25mg (£79.99, weeks 1-4), 0.5mg (£94.99, weeks 5-8), 1mg (£99.99, weeks 9-12), 1.7mg (£139.99, weeks 13-16), and 2.4mg maintenance (£209.99, week 17 onwards). These prices include discount code FIRST40 for new customers and DOSE25 for returning patients, applied automatically at checkout through our GPhC-registered pharmacy (#9012878). The total cost for initial 16-week escalation reaches £514.96, followed by consistent monthly maintenance costs of £209.99.
Bundle options provide supply security without necessarily reducing individual pen costs: the Intro Duo (0.25mg & 0.5mg) costs £169.99, while the Ultimate Stability Trio offers three months of 2.4mg maintenance for £649.99. When considering a change from Wegovy to Mounjaro monthly cost implications, patients should calculate both escalation and long-term maintenance expenses, as Mounjaro's dual GIP/GLP-1 mechanism may require different dose scheduling that affects overall treatment investment.
Clinical Evidence Informing Cost-Effectiveness of Switching
The STEP trials demonstrated Wegovy's efficacy with approximately 15% average weight loss at 68 weeks alongside reduced-calorie diet and increased physical activity (Wilding et al., NEJM, 2021). STEP 5 showed sustained clinically studied weight loss at 2 years, while the SELECT trial revealed 20% reduction in major cardiovascular events. These outcomes may inform cost-effectiveness calculations when considering a change from Wegovy to Mounjaro monthly expenses.
Mounjaro's clinical trials showed different efficacy profiles due to its dual GIP/GLP-1 receptor mechanism, though direct comparison between trials isn't appropriate due to different study designs and patient populations. When evaluating monthly costs, patients should discuss both medications' clinical evidence with their prescriber to determine which treatment offers the best value for their individual circumstances and health goals.
How Wegovy Works: GLP-1 Mechanism and Monthly Investment
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics natural fullness hormones to reduce appetite and promote satiety after smaller meals. This prescription-only medicine works by acting on brain appetite centres, potentially reducing food cravings while supporting weight management alongside lifestyle modifications. The once-weekly FlexTouch injection delivers consistent medication levels, requiring gradual dose increases over 16 weeks to minimise side effects. Understanding Wegovy's mechanism helps justify the monthly cost investment, as the medication provides sustained appetite suppression rather than short-term effects. The structured escalation protocol ensures optimal therapeutic response while managing tolerability, making each monthly payment part of a comprehensive treatment strategy designed for long-term weight management success.
Streamlined Ordering Process for Both Medications
EverydayMeds offers identical ordering processes whether continuing Wegovy or switching to Mounjaro, eliminating administrative barriers to treatment changes. The 3-minute online clinical assessment covers medical history, current medications, and treatment goals, followed by prescriber review within standard 3 working days or express 24-hour service. Once approved, both medications ship via next-day delivery using temperature-controlled cold-chain storage to maintain medication integrity. This streamlined process means patients considering a change from Wegovy to Mounjaro monthly cost implications can access either treatment without delays or complex switching procedures. Payment processing accepts all major cards with automatic discount code application, ensuring transparent pricing at checkout for both treatment options.
Storage Requirements and Practical Cost Considerations
Wegovy requires refrigeration at 2-8°C before first use, but offers significant travel flexibility with 6 weeks room temperature storage below 30°C once removed from the fridge. This storage advantage over Mounjaro's 21-day room temperature limit may influence total cost of ownership, particularly for frequent travellers who might otherwise need replacement pens due to storage violations. The FlexTouch pen design ensures precise dosing throughout the 16-week escalation and ongoing maintenance phases, minimising waste and maximising value from each monthly purchase. Proper storage protects your medication investment while ensuring consistent therapeutic effects that justify the monthly cost commitment. Understanding these practical factors helps patients make informed decisions about change from Wegovy to Mounjaro monthly cost implications beyond simple price comparison.
Long-Term Budgeting: Annual Costs and Financial Planning for Treatment Switches
Annual Wegovy costs reach approximately £2,734.84 after initial escalation (£514.96) plus 10 months maintenance (£2,099.90), while Mounjaro follows different pricing patterns that may affect yearly budget planning. Patients considering a change from Wegovy to Mounjaro monthly cost implications should calculate both first-year escalation expenses and subsequent annual maintenance costs to understand true financial commitment. The DOSE25 discount code ensures returning customers maintain competitive pricing throughout their treatment journey, providing cost predictability for long-term planning.
Financial planning becomes particularly important given clinical evidence showing weight regain when treatment discontinues - STEP 1 extension demonstrated patients regained approximately two-thirds of lost weight within one year of stopping medication. This data suggests weight management represents a long-term financial commitment rather than short-term expense, making monthly cost comparisons crucial for sustainable treatment selection and budgeting decisions.
Expert Guidance: Making Cost-Effective Treatment Decisions
Both Wegovy and Mounjaro are available from EverydayMeds, and your prescriber can help determine which medication offers the best value for your specific circumstances and health goals. Clinical assessment considers not just monthly costs but also individual response patterns, side effect profiles, and long-term treatment objectives when evaluating a change from Wegovy to Mounjaro. Our qualified prescribers provide comprehensive consultation to ensure treatment selection balances clinical effectiveness with financial sustainability, supporting informed decision-making about medication switches. Start your assessment today at https://everydaymeds.co.uk/collections/wegovy using code FIRST40 for new customers or DOSE25 for returning patients to access transparent, competitive pricing for either treatment option. Remember that both medications require ongoing commitment alongside reduced-calorie diet and increased physical activity for optimal results and cost-effectiveness.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
